in function that has adverse impacts on their usual activities, such as social activities, body image, emotional well-being, and so on. 4 At present, there is no treatment that has been shown to prevent the progression of OA, and the current treatments which include lifestyle modification, surgery, and pharmaceutical drugs all aim at structural modification and symptom improvement. 5 Currently, the most widely prescribed drugs for OA are nonsteroidal antiinflammatory drugs (NSAIDs), while traditional NSAIDs (inhibiting both cyclo-oxygenase (COX) -1 and COX-2) have serious adverse effect on gastrointestinal tract resulting from its role in inhibiting COX-1, which is thought to protect the GI mucosa by the synthesis of prostaglandin. 6, 7 Subsequently, the selective COX-2 inhibitors are developed and present with a better therapeutic effect and a safer gastrointestinal profile through sparing COX-1 compared to traditional NSAIDs. 2, 5 Celecoxib, as one of the most frequently used selective COX-2 inhibitors, has also been reported to be highly effective and well tolerated in OA patients with the advantage of better renal safety profile and lower incidence of gastrointestinal adverse events compared to traditional NSAIDs, including ibuprofen and diclofenac. 1, 2, 8, 9 However, the molecular mechanisms underlying the clinical effect in alleviating pain and function improvement of celecoxib in knee OA patients has not been fully elucidated.
MicroRNAs (miRNAs), a family of small non-coding RNAs with
21-28 nucleotides in length, regulate gene expression by inhibiting RNA translational and/or promoting mRNA degradation though binding to specific binding site in the 3′ untranslated region (UTR)
of their target mRNAs. 10 Several miRNAs are reported to show tissue-specific or developmental stage-specific expression profile associated with various join-related diseases, including joint disorders, rheumatoid arthritis (RA), and OA. 11 For example, Zi Wang et al 12 reveal that the expression of miR-140-5p and miR-149 was significantly down-regulated in knee OA patients compared with the healthy controls (HCs), and low expression of miR-140-5p/149
inhibit chondrocyte proliferation and autophagy by targeting fucosyltransferase 1 (FUT1). As miRNAs are involved in the pathogenesis of OA development and progression, and celecoxib is observed to regulate a number of miRNAs in several diseases, [13] [14] [15] [16] we hypothesized that celecoxib treatment would modulate miRNA expression profiles in knee OA.
Thus, this study aimed to investigate the change of circulating miRNA expression profiles in knee OA patients before and after celecoxib treatment. 
| MATERIAL S AND ME THODS

| Patients
| Ethics statement
| Study design
The study design is presented in Figure 1 . 441 knee OA patients were invited to participate in this study, while 85 were excluded (14 missed the invitation and 71 declined to participate); thus, the remaining 356 knee OA patients were screened for eligibility. Among the 356 screened knee OA patients, 73 were excluded (29 exclusions and 44 disagreed to sign the informed consents); therefore, 283 knee OA patients were enrolled and received celecoxib treatment for 6 weeks. Among the study duration, 65 patients withdrew the study (3 lacked efficiency, 4 withdrew the consents, 18 stopped celecoxib in advance, and 40 lost follow-up); hence, 218 knee OA patients completed the protocol and were included in the analysis.
In the exploration stage, 6 knee OA patients were randomly selected, and plasma sample was obtained before initiation of treatment (W0) and at 6 weeks (W6) after celecoxib treatment. And miRNA profiles in plasma were subsequently detected by microarray (GeneChip miRNA 4.0 Array (Affymetrix, USA)). Then, principal components analysis (PCA), heat map, and GO analysis for miRNA profiles before and after celecoxib treatment were performed, and 10 top differentially expressed miRNAs (DEMs) were selected for validation ( Figure 1 ).
In the validation stage, plasma sample was obtained before initiation of celecoxib treatment (W0) and at W6 after celecoxib treatment in 218 knee OA patients. And qPCR assay was performed to determine the expressions of 10 candidate miRNAs at W0 and W6.
| Treatment and assessments
All knee OA patients received celecoxib treatment for 6 weeks according to disease conditions and patients' willingness as follows: 
| qPCR assay
In the validation stage, qPCR assay was used to detect the 10 top DEMs that were identified in exploration stage by microarray. In brief, total RNA was extracted from each plasma sample of 218 knee OA patients by Trizol LS RNA isolation kit (Invitrogen, USA) and then reversely transcribed into cDNAs by Transcript First-strand cDNA synthesis superMix (TransGen Biotech, China). Afterwards, SYBR Premix Ex Taq kit (Takara, China) was performed to detect the DEMs, while the data of DEMs were normalized according to the expression of U6. After that, the results were analyzed using SDS 1.4 software according to the 2 −ΔΔCt method.
| Statistics
Statistical analysis was performed using the SPSS 22.0 (IBM, USA), GraphPad Prism 6 (GraphPad Software, USA) and R software 3.2.5
(MathSoft, USA). Data were mainly described as mean value ± standard deviation or count (percentage). Difference between two groups was determined by paired t test, Wilcoxon signed-rank sum test or t test. A 2-tailed P value <0.05 was considered statistically significant.
| RE SULTS
| Baseline characteristics of knee OA patients in exploration stage
The overall demographic and clinical characteristics of knee OA patients (N = 6) in exploration stage are listed in 
| Treatment efficiency of knee OA patients in exploration stage
In the exploration stage, the WOMAC pain score (P = 0.006, Figure 2A ), WOMAC stiffness score (P = 0.003, Figure 2B ), and WOMAC physical function score (P = 0.003, Figure 2C ) in 6 knee OA patients were all declined at W6 compared with W0. In addition, at 6 weeks postcelecoxib treatment, 67% of knee OA patients achieved clinical response, while 33% of them failed to realize clinical response ( Figure 2D ).
| DEM analysis and enrichment analysis by microarray
Principal components analysis plot analysis was conducted to evaluate the difference of miRNAs aggregate in knee OA patients before and after celecoxib treatment, which showed that miRNA expression profiles could clearly distinguish knee OA patients before and after treatment in comp_2 axe ( Figure 3A ), while in comp_1 axe and comp_3 axe ( Figure 3B ), the miRNAs expression could not separate knee OA patients before and after treatment. 
| Top 10 DEMs by microarray
Top 10 DEMs were selected in microarray according to their P values (Table 2) , which consisted of 6 up-regulated miRNAs, miR-126-5p, miR320a, miR-210, miR-3197, miR-4796, and miR-92a-3p, and 4 downregulated miRNAs, miR-675-3p, miR-155-5p, miR-17-3p, and miR-146a-5p.
| Baseline characteristics of knee OA patients in validation stage
Baseline characteristics of 218 knee OA patients in validation stage are shown in Table 3 with mean age 57.3 ± 11.7 years, female 165 
The PCA plot analysis. The red and blue text represents samples of before and after treatment, respectively. PCA plot showed that in comp_2 axe (A), knee OA patients before and after celecoxib treatment could be distinguished by miRNA expression profiles, while the differences of miRNA expressions between knee OA patients before and after treatment were not found in comp_1 axe (A) as well as in comp_3 axe (B). The PCA plot analysis was used to evaluate the difference of miRNA expression profiles for distinguishing knee OA patients before and after celecoxib treatment (Comp_1, Comp_2 and Comp_3 stand for three principal components respectively). OA, osteoarthritis; PCA, principal component analysis
| Treatment efficiency of knee OA patients in validation stage
In the validation stage, the WOMAC pain score (P < 0.001, Figure 6A ), WOMAC stiffness score (P < 0.001, Figure 6B ), and WOMAC physical function score (P < 0.001, Figure 6C ) in knee OA patients at W6 were all decreased in comparison with W0. What's more, after celecoxib treatment for 6 weeks, 71% of knee OA patients realized clinical response, while the remaining 29% were failed ( Figure 6D ).
F I G U R E 4
Volcano map and heat map analysis of DEMs. Volcano plot displayed 45 up-regulated and 48 down-regulated DEMs (A) and heat map analysis showed that knee OA patients before and after celecoxib treatment can be distinguished by dysregulated DEMs (B). DEMs was compared by R package limma, Benjamini as well as Hochberg procedure was used to adjust P values, and clinical significance defined as a difference of 1.5 folds (absolute (log2 (fold change))>1.5). OA, osteoarthritis; DEMs, differentially expressed miRNAs F I G U R E 5 Enrichment analysis. Enrichment analysis showed that the DEMs were mostly associated to the inflammatory responses (A) (IL-1, cartilage, NLRP3 inflammasome, cytokine, and leukocyte) and pathways (NF-kappa B, IL-2, TNF, Toll-like receptor, or insulin signaling) related to OA (B). Enrichment analysis of DEMs and its precursor was completed by Fisher's exact test to identify over-represented miRNArelated items. OA, osteoarthritis; DEMs, differentially expressed miRNAs; IL, interleukin; TNF, tumor necrosis factor
| Comparison of candidate miRNAs expressions before and after treatment in validation stage
After 6 weeks of celecoxib treatment, miR-126-5p (P < 0.001, Figure 7B ) and miR-320a (P = 0.004, Figure 7D ) levels were elevated in knee OA patients compared with W0, while miR-155-5p (P < 0.001, Figure 7C ) and miR-146a-5p (P = 0.001, Figure 7H ) levels were decreased. However, no difference concerning the levels of miR-675-3p (P = 0.089, Figure 7A ), miR-210 (P = 0.145, Figure 7E ), miR-3197 (P = 0.269, Figure 7F ), miR-17-3p (P = 0.109, Figure 7G ),miR-4796 (P = 0.191, Figure 7I ), or miR-92a-3p ( Figure 7J) (P = 0.770) between W6 and W0 was found.
| Comparison of changes of candidate miRNAs expressions (W6-W0) between clinical response patients and nonclinical response patients treated by celecoxib
MiR-126-5p level was increased at W6 both in clinical responders and nonclinical responders, while its increase in clinical responders was much larger than that in nonclinical responders (P = 0.037, Figure 8B ). The expression of miRNA-320a was declined in nonclinical responders while increased in clinical responders (P = 0.012, Figure 8D ). Conversely, the expression of miRNA-146a-5p was increased in non-clinical responders while decreased in clinical responders (P = 0.004, Figure 8H ). No difference of the relative change in expression of miR-675-3p (P = 0.986, Figure 8A ), miR-155-5p (P = 0.079, Figure 8C ), miR-210 (P = 0.566, Figure 8E ), miR-3197 (P = 0.459, Figure 8F ), miR-17-3p (P = 0.606, Figure 8G ), miR-4796 (P = 0.950, Figure 8I ), or miR-92a-3p (P = 0.515, Figure 8J ) was detected between clinical responders and nonclinical responders.
| D ISCUSS I ON
Our study disclosed that (a) knee OA patients after celecoxib treatment could be differentiated from them before treatment Physical function 61.7 ± 12.9
Data were presented as mean value ± standard deviation or counts (% Those results suggest that miR-155-5p has negative effects in OA through enhancing inflammation by regulating several cytokines production, which might explain the lower level of miR-155-5p in knee OA patients after celecoxib treatment compared with baseline in our study; however, the difference of the relative change of miR-155-5p expression between nonclinical responders and clinical responders did not present statically significant, which might be resulted from the relative small sample size in this study or the weak correlation between miR-155-5p expression and PGART score. As for miR-146a-5p, a previous in vivo experiment
illuminates that miR-146a is overexpressed in human chondrocyte
Comparison of changes of candidate miRNAs expressions (W6-W0) between clinical response patients and nonclinical response patients. MiR-126-5p level in knee OA patients was increased at W6 compared to W0, and its increase level in clinical responders was much larger than that in non-clinical responders (B). MiRNA-320a level was declined in non-clinical responders while was increased in clinical responders (D). Conversely, miRNA-146a-5p level was increased in non-clinical responders while was decreased in clinical responders (H). No difference of the expression of miR-675-3p (A), miR-155-5p (C), miR-210 (E), miR-3197 (F), miR-17-3p (G) (P = 0.606), miR-4796 (I) (P = 0.950), or miR-92a-3p (J) (P = 0.515) was detected between clinical responders and nonclinical responders. Difference between clinical responders and nonclinical responders was determined by t test. P < 0.05 was considered statistically significant. OA, osteoarthritis; W, week after mechanical pressure injury and may contribute to the pathogenesis of OA by stimulating vascular endothelial growth factor production and damaging the transforming growth factor (TGF)-β signaling pathway through the targeted inhibition of Smad4 in cartilage. 24 In another observational study, Yamasaki et al 20 illustrate
that miR-146a is highly expressed in OA cartilage compared with normal cartilage, and its expression is induced by the stimulation of interleukin (IL)-1β. In addition, there is also a study illuminating that miR-146a and miR-155 are upregulated in more advanced knee OA patients. To be exact, Soyocak A et al 25 elucidate that miR-146a
and miR-155 expressions are elevated in peripheral blood mononuclear cell (PBMC) of knee OA patients in progressive stages. In accordance with these findings, our study found that miR-146a-5p is low expressed in knee OA patients after celecoxib treatment, and its level was decreased in clinical responders while was increased in nonclinical responders, which could be explained by the destructive role of miR-146a-5p in cartilage and its regulatory function of inflammatory factors discovered by the previous studies. 24, 26 Some limitations existed in this study: (a) The sample size in this study was relatively small, which may lead to lower statistical efficiency than studies with larger sample size; (b) all patients enrolled in this study were from single center, which might cause selection bias. Thus, further study enrolling patients from multicenter is required. (c) The cut-off point of PGART score which was used to predict clinical response in knee OA patients is selfdefined because of without a universally standard. However, it remains to be verified which cut-off value for clinical response is the most clinically relevant.
In conclusion, our results defined a profile of knee OA-related dysregulated miRNA signatures that significantly different in knee OA patients before and after celecoxib treatment, revealing that these miRNAs might play important role in knee OA pathogenesis and celecoxib-mediated therapeutics.
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